Publications by authors named "Kristen Needham"
Article Synopsis
- * Research indicates that the effectiveness of this combination is hindered by its inability to induce cell death (apoptosis), despite changes in related proteins, suggesting that MCL-1 and BCL-X are overexpressed in BRAF CRCs.
- * Combining encorafenib with BCL-X inhibitors has shown promise in enhancing apoptosis in cancer cells, with one experimental approach (DT2216) resulting in increased cell death in lab tests and successful tumor growth reduction
Human epidermal growth factor receptor-2 (HER2)-targeting therapies provide clinical benefits for patients with HER2-positive breast cancer. However, the resistance to monotherapies invariably develops and leads to disease relapse and treatment failure. Previous studies have demonstrated a link between the potency of HER2-targeting tyrosine kinase inhibitors (TKIs) and their ability to induce an iron-dependent form of cell death called ferroptosis.
View Article and Find Full Text PDF